Adam Rauch

I've spent my career on the commercial side of contract research. I started at Accelevir Diagnostics, a CAP/CLIA-certified bioanalytical CRO spun out of Johns Hopkins, and since 2024 I've also worked with Noble Life Sciences, a preclinical in vivo CRO in Sykesville, Maryland. I find new sponsors, run scoping calls, write the quotes and SOWs, and build the partnerships that let a smaller CRO bid on larger programs.

In the past 12 months I've written hundreds of quotes and SOWs, from rodent PK studies to GLP toxicology in swine and large-animal device studies. That volume taught me what makes a study easy to quote, what makes a quote easy to sign, and where both go wrong.

Biotech teams kept asking me the next question: once the data is in, who should see it? So I also help emerging biotechs with partnering, research collaborations and investor readiness. I've put together partnerships between CROs, I'm building a multi-company network to cover IND-enabling programs end to end, and I know what's inside a preclinical data package, which is the first thing partners and investors diligence.

I started Lead Compound Advisory to bring all of that to more CROs and to the biotechs that work with them. The name has two meanings on purpose: CROs need the right leads, and biotechs need the right partners for their lead compound.